As MF progresses, there is a decline in anti-tumor Th1 responses (e.g., IFN-γ, IL-12) and a predominance of Th2 cytokines such as IL-4, IL-5, and IL-13 [16,28]. The gene discussed is IL13; the disease is neoplasm.